Business NewsPR NewsWire • EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)

TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME).  Bayer...

View More : http://www.prnewswire.com/news-releases/eylea-aflibercept-injection-receives-eu-approval-for-the-treatment-of-diabetic-m...
Releted News by prnewswire
Novartis to showcase heart failure leadership at ESC Congress 2014 with results on new first of its type medicine LCZ696
Beeline Announces Merger With OnForce
Beeline annonce la fusion avec OnForce
EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Diabetic Macular Edema (DME)
Cellcom Israel Announces Second Quarter 2014 Results
Beeline gibt Fusion mit OnForce bekannt